June 20, 2024 07:10 AM EDTUpdated 08:22 AM

Lilly cracks down further on compounded tirzepatide as GLP-1 shortage starts to ease

Ayisha Sharma

News Reporter

Eli Lilly is filing a fresh round of lawsuits against medspas, wellness centers and other entities that it claims are selling compounded versions of its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly cracks down further on compounded tirzepatide as GLP-1 shortage starts to ease

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Steve Davis leaves Acadia, replaced by Bristol Myers alum; Former J&J exec to lead R&D at Novavax

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

US government renews threats over J&J's proposed 340B rebate model

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Lil­ly cracks down fur­ther on com­pound­ed tirzepatide as GLP-1 short­age starts to ease

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Lilly cracks down further on compounded tirzepatide as GLP-1 shortage starts to ease